Biomarkers of response and resistance to antiangiogenic therapy - PubMed (original) (raw)
Review
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K Jain et al. Nat Rev Clin Oncol. 2009 Jun.
Abstract
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
Figures
Figure 1
Candidate biomarkers of response and resistance to antiangiogenic therapy. At baseline, the genotype of VEGF and/or IL-8 might associate with outcome of bevacizumab with chemotherapy. Randomized trials will establish if the biomarkers are predictive or prognostic. Among dynamic biomarkers, the extent of hypertension, decrease in Ktrans (in patients with glioblastoma or hepatocellular carcinoma), increase in small (cerebral) blood vessel volume (glioblastoma) and/or increase in circulating collagen IV (glioblastoma) might be predictive of outcome of antiangiogenic therapy. Finally, molecular pathways such as SDF1α (in glioblastoma, hepatocellular carcinoma or renal-cell carcinoma), IL-6 (in hepatocellular carcinoma or renal-cell carcinoma) or bFGF (glioblastoma), and CPCs (in hepatocellular carcinoma) might be associated with resistance to antiangiogenic therapy. Abbreviations: bFGF, basic fibroblast growth factor, CBV, cerebral blood volume; CPC, circulating progenitor cell; IL, interleukin; LDH, lactate dehydrogenase; SDF1α, stromal-cell-derived factor 1α; sICAM1, soluble intracellular adhesion molecule 1.
Figure 2
Modes of vessel recruitment to tumors that might be involved in tumor escape from antiangiogenic therapy. Abbreviations: bFGF, basic fibroblast growth factor; BMC, bone marrow cell; IL-6, interleukin 6; SDF1α, stromal-cell-derived factor 1α. Adapted with permission from Nature Publishing Group © Carmeliet, P. and Jain, R. K. Nature 407, 249–257 (2000).
Similar articles
- Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A, Jöhrer K, Kocher F, Steiner N, Graziadei I, Heidegger I, Pichler R, Leonhartsberger N, Kremser C, Kern J, Untergasser G, Gunsilius E, Hilbe W. Pircher A, et al. Oncotarget. 2016 Apr 12;7(15):20109-23. doi: 10.18632/oncotarget.7915. Oncotarget. 2016. PMID: 26956051 Free PMC article. - Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S, Rich JN. Sathornsumetee S, et al. Curr Pharm Des. 2007;13(35):3545-58. doi: 10.2174/138161207782794130. Curr Pharm Des. 2007. PMID: 18220791 Review. - Antiangiogenic therapy in oncology: current status and future directions.
Jayson GC, Kerbel R, Ellis LM, Harris AL. Jayson GC, et al. Lancet. 2016 Jul 30;388(10043):518-29. doi: 10.1016/S0140-6736(15)01088-0. Epub 2016 Feb 5. Lancet. 2016. PMID: 26853587 Review. - Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN, Coleman RL, Sood AK. Bottsford-Miller JN, et al. J Clin Oncol. 2012 Nov 10;30(32):4026-34. doi: 10.1200/JCO.2012.41.9242. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008289 Free PMC article. Review. - Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM, LaBonte MJ, Lenz HJ. Wilson PM, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Cancer Chemother Pharmacol. 2013. PMID: 23053262 Review.
Cited by
- CD133-containing microvesicles promote colorectal cancer progression by inducing tumor angiogenesis.
Kim B, Kim S, Park S, Ko J. Kim B, et al. Heliyon. 2024 Apr 4;10(7):e29292. doi: 10.1016/j.heliyon.2024.e29292. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38601650 Free PMC article. - Translational research on drug development and biomarker discovery for hepatocellular carcinoma.
Chew V, Chuang CH, Hsu C. Chew V, et al. J Biomed Sci. 2024 Feb 17;31(1):22. doi: 10.1186/s12929-024-01011-y. J Biomed Sci. 2024. PMID: 38368324 Free PMC article. Review. - Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy.
Yin J, Dong F, An J, Guo T, Cheng H, Zhang J, Zhang J. Yin J, et al. Theranostics. 2024 Jan 20;14(3):1312-1324. doi: 10.7150/thno.89306. eCollection 2024. Theranostics. 2024. PMID: 38323316 Free PMC article. - Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key.
Drzał A, Dziurman G, Hoła P, Lechowski J, Delalande A, Swakoń J, Pichon C, Elas M. Drzał A, et al. Int J Mol Sci. 2023 Jul 29;24(15):12156. doi: 10.3390/ijms241512156. Int J Mol Sci. 2023. PMID: 37569531 Free PMC article. - Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Chamseddine S, et al. Oncology. 2023;101(11):730-737. doi: 10.1159/000531870. Epub 2023 Aug 23. Oncology. 2023. PMID: 37467732 Free PMC article.
References
- Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. - PubMed
- Jain RK. Molecular regulation of vessel maturation. Nat. Med. 2003;9:685–693. - PubMed
- Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186. - PubMed
- Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–2342. - PubMed
- Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007;357:2666–2676. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-CA 85140/CA/NCI NIH HHS/United States
- R21 CA099237/CA/NCI NIH HHS/United States
- R01-CA 129371/CA/NCI NIH HHS/United States
- R01 CA 57683/CA/NCI NIH HHS/United States
- P41-RR 14075/RR/NCRR NIH HHS/United States
- P01 CA080124/CA/NCI NIH HHS/United States
- R01 CA126642-01A1/CA/NCI NIH HHS/United States
- P41 RR014075-01A1/RR/NCRR NIH HHS/United States
- P01 CA080124-01A1/CA/NCI NIH HHS/United States
- R01 CA126642-04/CA/NCI NIH HHS/United States
- K24 CA125440-05/CA/NCI NIH HHS/United States
- R21-CA 117079/CA/NCI NIH HHS/United States
- R21 CA117079-02/CA/NCI NIH HHS/United States
- R01 CA129371-05/CA/NCI NIH HHS/United States
- R01 CA126642/CA/NCI NIH HHS/United States
- R01 CA085140-10/CA/NCI NIH HHS/United States
- R21 CA117079/CA/NCI NIH HHS/United States
- R01 CA085140/CA/NCI NIH HHS/United States
- R01 CA129371/CA/NCI NIH HHS/United States
- P01 CA080124-10/CA/NCI NIH HHS/United States
- P41 RR014075/RR/NCRR NIH HHS/United States
- K24 CA125440/CA/NCI NIH HHS/United States
- R01 CA115767-05/CA/NCI NIH HHS/United States
- R01 CA 126642/CA/NCI NIH HHS/United States
- R01-CA 115767/CA/NCI NIH HHS/United States
- P01-CA 80124/CA/NCI NIH HHS/United States
- M01 RR001066/RR/NCRR NIH HHS/United States
- R01 CA115767-01A1/CA/NCI NIH HHS/United States
- R01 CA057683/CA/NCI NIH HHS/United States
- M01-RR 01066/RR/NCRR NIH HHS/United States
- R21-CA 99237/CA/NCI NIH HHS/United States
- K24-CA 125440/CA/NCI NIH HHS/United States
- R21 CA099237-01A1/CA/NCI NIH HHS/United States
- R01 CA115767/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources